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Abstract 
Background 
Repeated episodes of limb ischaemia and reperfusion (remote ischaemic conditioning, RIC) 
may protect the brain from ischaemic reperfusion injury. 
 
Methods and Results 
We performed a phase IIb blinded dose-escalation sham-controlled trial in patients with 
hyperacute stroke, randomised 1:1 to receive RIC (four 5-minute cycles) or sham to the non-
paretic upper limb, in 3 blocks of increasing dose, starting within 6 hours of ictus. The primary 
outcome was trial feasibility (recruitment, attrition). Secondary outcomes included 
adherence, tolerability, safety (serious adverse events [SAE]), plasma biomarkers at day 1 
and 4 (S100-ß protein, matrix metalloproteinase-9 (MMP-9) and neurone specific enolase 
(NSE)) and functional outcome. Sixty participants were recruited from two centres (3/month) 
with no loss to follow-up: time to randomisation 4hr 5min (standard deviation 72min), age 72 
(12), male 60%, blood pressure 154/80mmHg (25/12), NIHSS 8.4 (6.9) and 55% 
thrombolysed. RIC was well tolerated with adherence not differing between RIC and sham, 
falling in both groups on day 3 (p=0.001, repeated measures ANOVA) due to discharge or 
transfer. S100ß increased in the sham (mean rise 111pg/ml (302), p=0.041, repeated 
measures ANCOVA) but not RIC group. There were no differences in MMP-9, NSE, number 
with SAE (RIC 10 v sham 10, p=0.81), deaths (2 v 4, p=0.36) or modified Rankin score (2 
[interquartile range 1-4], 2 [1-3], p=0.85). 
 
Conclusions 
RIC in hyperacute stroke is feasible when given twice daily for two days and appears safe 
in a small population with hyperacute stroke. A larger phase III trial is warranted. 
 
ClinicalTrials.gov Identifier: NCT02779712 
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Clinical Perspective 
• This is the first randomised controlled trial in hyperacute ischaemic stroke testing an 
increasing dose of remote ischaemic conditioning; repeated dosing until day two was 
feasible in terms of adherence, and the dosing regimen for larger RIC trials should 
consider this alongside local patient pathways. 
• Beneficial clinical signals exist from several small pilot and proof-of-concept studies 
using RIC after stroke and these findings warrant further testing in a well-designed, larger 
phase III trial.  
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BACKGROUND 
Remote ischaemic conditioning (RIC) uses repeated cycles of transient limb ischaemia and 
reperfusion to induce organ protection from ischaemic reperfusion injury and tolerance to 
subsequent ischaemic events. The mechanisms underlying RIC are not fully understood but 
have been attributed to neuro-humoral pathways linking the pre-conditioned tissue to the 
brain, resulting in early and late windows of protection.1, 2 
 
Experimentally, RIC applied before (pre-conditioning), during (per-conditioning) and after 
(post-conditioning) an ischaemic stroke decreases cerebral inflammation and oedema, and 
reduces apoptosis in the ischaemic penumbra through inhibition of the mitochondrial 
permeability transition pore (MPTP).3-5 Administration of a protein synthesis inhibitor, 
afferent nerve blocker or KATP channel antagonist attenuates the neuroprotective effects of 
RIC.4, 6 In meta-analysis of pre-clinical stroke, remote pre- per- and post-conditioning 
reduced infarct volume by 35%, was effective in permanent and transient models of 
ischaemia, and improved neurological outcome.7 
 
Five proof-of-concept randomised clinical trials in stroke and RIC have been published: in 
populations prior to carotid stenting (pre-conditioning),8 in acute ischaemic stroke (per-
conditioning),9, 10 and after ischaemic stroke caused by intracranial stenosis (post-
conditioning).11, 12 In the Remote Ischaemic Conditioning After Stroke Trial (RECAST-1), we 
demonstrated excellent intervention tolerability in patients with acute stroke;10 although 
limited by a small sample size, there was also a significant decrease in National Institutes 
for Health Stroke Scale (NIHSS) score at day 90, and augmentation of neuroprotective 
proteins, plasma HSP27 and phosphorylated HSP27, in the RIC group.13 
 
In the current study, we aimed to demontrate feasibility and safety of increasing doses of 
remote ischaemic per-conditioning in patients presenting to hospital with hyperacute stroke. 
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METHODS 
 
Trial Design 
The Remote ischaemic Conditioning After Stroke Trial 2, RECAST-2, was a two-centre, 
feasibility, dose-escalation, outcome blinded, randomised placebo-controlled trial. The trial 
was conducted in accordance with the Declaration of Helsinki and the International 
Conference of Harmonisation of Good Clinical Practice (ICH-GCP), sponsored by the 
University of Nottingham (UK), received authorisation from the Local Research Ethics 
Committee (LREC, West Midlands, 15th April 2016) and was a registered clinical trial 
(NCT02779712). 
 
Subjects 
Adults ≥18 years were invited to participate if they had a clinical stroke with onset in the last 
6 hours. Exclusion criteria were premorbid dependency (modified Rankin Scale >3), 
dementia, Glasgow Coma Score <8, malignancy, pregnancy and significant co-morbidity. 
We did not mandate that baseline neuroimaging (as part of standard care) was required 
before randomisation, but in practice, the brain scan and approaching the participant for the 
trial occurred in parallel, with the result available prior to trial inclusion. The trial recruited 
patients from University Hospitals of Derby and Burton (UHDB) NHS Foundation Trust and 
Nottingham University Hospitals (NUH) NHS Trust in the UK between August 2016 and April 
2018.  UHDB and NUH receive approximately 900 and 1300 strokes per year respectively. 
Consent was obtained by the research practitioner from each patient or legal representative 
if the patient was unable to consent. Clinical and safety assessments were performed at 
baseline (pre-randomisation), day 4 (face-to-face) and day 90 (telephone).  
 
Intervention 
RIC was performed by trained trial staff immediately after randomisation and included 4 
cycles of intermittent limb ischaemia: alternating 5 minutes inflation (20 mmHg above 
systolic BP) followed by 5 minutes deflation of a standard upper arm blood pressure cuff in 
the non-paretic arm. The control group received a sham procedure mimicking the 
intervention protocol but cuff inflation only reached 30 mmHg. The intervention was 
performed manually using a standard BP cuff. Preclinically, repeated RIC cycles is more 
effective than a single set of cycles,14 hence we increased the dose in three phases: the first 
20 participants received one ‘dose’ of RIC/sham, i.e. 4 cycles of cuff inflation and deflation; 
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participants 21-40 received a second dose (4-cycles of RIC/sham) one hour after the first 
dose; and the final 20 participants (41-60) were also administered twice daily dosing starting 
the following morning up to and including day 4 (total 8 doses). Delivery time of each cycle 
was recorded (seconds) and reasons for discontinuation. 
 
Primary Outcome 
The primary outcome was trial feasibility describing recruitment rate, time to recruitment, 
number recruited per centre, and attrition to follow up. 
  
Secondary Outcomes 
Tolerability  
Tolerability of increasing doses of RIC: duration cuff tolerated, number of cycles, 
adherence to RIC and reasons for poor adherence. 
 
Clinical measures and safety 
Clinical secondary outcomes included safety: vascular events (recurrent stroke, myocardial 
infarction, limb ischaemia and venous thrombo-embolism), death, neurological deterioration 
(ND, increase in NIHSS >4 points), neurovascular limb damage and tissue injury. 
Comparison of serious adverse events (SAE) by treatment with thrombolysis provided a 
further assessment of safety in this subgroup. Function was assessed at day 90 by 
telephone interview blinded to treatment allocation: dependency (mRS),15 disability (Barthel 
Index),16 Zung depression scale,17 quality of life (EQ-5D) and cognition (TICS-M).18  
 
Laboratory measures  
Immediately prior to treatment and on day 4 (±1), blood samples were collected for (i) 
surrogate markers of brain injury, which might be attenuated if RIC improves ischaemic 
reperfusion injury (plasma S100ß protein, matrix metalloproteinase (MMP-9), neurone 
specific enolase (NSE), by multiplex technology, Merck Millipore Ltd, UK); S-100ß, NSE and 
MMP-9 also act as surrogate markers of infarct volume and prognosis in acute ischemic 
stroke.19, 20 (ii) Heat shock protein-27 (HSP-27, DouSet ELISA, R&D Systems, Abingdon, 
UK), is a biomarker implicated in the mechanisms of ischaemic conditioning 10 and is 
neuroprotective in experimental stroke.13 Assays and analysis of data were performed 
blinded to treatment allocation. 
 
JAHA submission, accepted version 25th Sept 2019 
 7 
Sample Size 
No formal power calculation was performed for this feasibility study. Considering resources, 
competing trials and time, recruiting 60 participants from two centres was deemed an 
appropriate number, at an anticipated rate of recruitment of 1.5 recruits per centre per 
month, to inform a larger trial on application of RIC in the hyperacute setting in terms of trial 
feasibility and increasing RIC dose. 
 
Randomisation and blinding 
Participants were recruited using web-based randomisation with computerised minimisation 
distributing the patients on a 1:1 ratio into RIC or sham groups. Minimisation variables were 
age (≥70), sex (male), NIHSS (≥10) and systolic BP (≥160 mmHg). The research practitioner 
delivering the intervention could not be blinded. Adjudicated serious adverse events and 
outcomes, day 90 interview, laboratory measures and statistical analyses were performed 
blinded to treatment allocation. 
 
Statistical Methods 
Baseline characteristics and functional outcomes of RIC and control groups were compared 
using Chi-squared or Fisher’s Exact test for binary data; continuous data are compared 
using t-test or Mann-Whitney U test; recurrent clinical events were compared using hazard 
ratios and univariate Cox-regression analyses (SPSS Statistics version 24). Additionally, 
day 90 mRS was compared using ordinal logistic regression. Repeated measures ANOVA 
with no co-variate adjustment compared adherence to treatment between groups. Repeated 
measures ANCOVA, adjusting for baseline NIHSS, compared plasma biomarkers taken on 
day 1 and day 4, with further adjustment using Sidak’s multiple comparisons test (SPSS 
Statistics version 24 and Prism 7 for Mac OS X version 7.0c). Associations between S100ß 
and functional outcome were tested using Pearson’s correlation coefficient. Subgroup 
analyses were not performed at a dose level since numbers were considered too small. Data 
in the figures are mean values ± standard deviation (SD) unless otherwise stated. Statistical 
significance was taken at p<0.05. 
 
Data Statement  
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. 
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RESULTS 
Subjects 
The trial commenced in August 2016, completed follow up in August 2018 and enrolled 60 
participants (31 and 29 in the RIC and sham groups respectively, 20 per dose block, Figure 
1). The mean age of all participants was 72 years (SD 12), 60% male, mean blood pressure 
(BP) 154/80 (SD 25/12) mmHg and median NIHSS 6 [interquartile range, IQR 3-11]. There 
were no baseline statistical differences between groups for age, sex and baseline stroke 
severity (Table 1). The RIC group were randomised later (254 versus 195 minutes, p=0.003), 
contained more participants with diabetes (33% versus 7%, p=0.02) and had a lower mean 
systolic BP (146 versus 162 mmHg, p=0.01). The final diagnosis was ischaemic stroke in 
55 (92%), transient ischaemic attack in 4 (7%) and functional disorder in 1 (2%). 
 
Trial Feasibility 
Recruitment rate averaged 1.5 participants per centre per month (n=20 centre 1, n=40 
centre 2). The main reasons for exclusion included presentation greater then 6 hours from 
onset of symptoms (42.5%), presenting outside of working hours (13.4%) and non-stroke 
diagnoses (12.5%) (Supplementary Table I). The median time to randomisation was 255 
minutes [IQR 186-298] with 33 (55%) receiving thrombolysis. There were no losses to follow-
up. The sham appeared feasible since when asked at day 90 which intervention they 
received, 56 (93%) did not know, 2 (4%) were incorrect and 2 (4%) correct.  
 
Compliance 
RIC was well tolerated with no statistical differences between RIC and sham regarding 
duration of cuff inflation (Figure 2). Adherence was high in the first 2 days but there was a 
significant fall on day 3 (dose 5) in RIC and sham groups to 40% and 43% respectively 
(p=0.001, repeated measures ANOVA), with no between group differences (p=0.64) 
secondary to either early discharge or the participant moving to another rehabilitation 
setting. In the first 48 hours, procedure intolerance in the RIC group (cuff pressure 
intolerance, headache, agitation) leading to incomplete treatment of 4 cycles occurred in 5 
of 62 (8%) offered doses (Supplementary Table II). 
 
Safety and clinical outcomes 
There was no difference in the number of participants with a SAE (Table 2 and 
Supplementary Table III) and no episodes of limb ischaemia or injury. Mortality was 10% 
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with 4 deaths in the sham group (n=1 extension/recurrent ischaemic stroke, n=1 
haemorrhagic transformation of infarction (HTI), n=1 early ND, n=1 gradual decline) and 2 
in the RIC group (n=1 HTI, n=1 malignancy). Extension and recurrent ischaemic stroke were 
more frequent in the sham group (6 versus 2 events, unadjusted HR 0.28, 95% confidence 
interval CI 0.06 - 1.37, p=0.12). 83% of recurrent cerebrovascular events occurred in the 
first 48 hours. RIC appeared safely administered in the thrombolysed cohort with no 
differences in SAEs between groups (Supplementary Table IV).  
 
Laboratory Measures 
Plasma S100ß increased significantly in the sham group from day 1 to day 4, mean 
difference (MD) 111 pg/ml (95% CI 5.6 – 216, p=0.041, repeated measures ANOVA, 
adjusted for baseline NIHSS, Figure 3). No differences in plasma S100ß were present in the 
RIC group between days 1 and 4 (MD 27.5 pg/ml 95% CI -14.5 – 69.5, p=0.187) nor were 
there significant differences between groups at day 4 (adjusted p=0.35). Day 4 Plasma 
S100ß correlated significantly with baseline NIHSS (Pearson’s correlation coefficient, 
r=0.561, p<0.001) and day 90 mRS (r=0.41, p=0.006). MMP-9 concentration was non-
significantly higher in the sham group compared to RIC (change from baseline, MD 15.3 
ng/ml (95% CI -2.6 – 33.2), p=0.09). There were no differences between groups with respect 
to NSE. Heat shock protein 27 assays proved unreliable and data is not presented. 
 
Functional outcomes 
There were no significant differences between groups with respect to functional outcomes, 
though the trial was not large enough to detect these (Table 3 and Figure 4). Telephone 
data collection at day 90 was feasible for measures of dependency (mRS), disability (BI), 
mood (Zung), cognition (TICS-M) and quality of life (EuroQoL), similar to other large trials.21  
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DISCUSSION 
The Remote ischaemic Conditioning After Stroke Trial 2 has demonstrated the feasibility of 
conducting a randomised controlled trial of remote ischaemic per-conditioning in hyperacute 
stroke across two centres in terms of recruitment, intervention delivery, attrition, compliance 
of increasing dose to day two, and use of an effective sham.  
 
RECAST-2 is the first stroke and RIC trial to evaluate alternative dosing strategies. Overall, 
the optimal dosing and method of application of RIC in stroke remains unclear. There is 
noticeable heterogeneity in completed and ongoing clinical trials ranging from daily 
administration using both arms in post-conditioning secondary prevention studies (cuff 
pressure to 200 mmHg),11, 12 to single lower limb application using cuff pressures 120 mmHg 
above the systolic BP in acute ischaemic stroke.22 Strategies appear to be based on the 
population studied rather than from information provided by pre-clinical data. Importantly, an 
experimental dose-finding study in post-conditioned stroke rats determined that 3 cycles of 
5min/5min limb ischaemia and reperfusion was more effective than 15sec/15sec and 
8min/8min.4. Previous trials have delivered RIC daily for up to 300 days,11, 12 initiated in the 
subacute phase post stroke; it is therefore feasible to deliver RIC for a prolonged period 
using an automated machine. We chose the maximum dose to stop at day 4 since this 
covers the hyperacute phase and prolonged effects of the treatment are anticipated.23 We 
also expected it would not be possible to administer RIC using a manual BP cuff for longer 
than this, which proved to be the case: in RECAST-2, repeated dosing until day two was 
feasible in terms of adherence, and the dosing regimen for larger RIC trials should consider 
this alongside local patient pathways. The main reason for treatment discontinuation was 
not cuff pressure intolerance but transfer of the participant to a different setting or discharge 
home. 
 
The absence of any serious adverse events relating to limb ischaemia or injury, especially 
in the thrombolysed cohort, is reassuring. The safety of RIC in hyperacute stroke, however, 
requires further evaluation since this is a small population. RIC has potential anti-platelet 
effects,24 which may be beneficial in ischaemic stroke, but could exacerbate haemorrhagic 
transformation of infarction or lead to deterioration if administered in intracerebral 
haemorrhage prior to confirmation of the diagnosis; one pre-hospital RIC trial, however, 
reported no clinical deterioration in thirty-seven participants with primary intracerebral 
haemorrhage.9 
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The majority of recurrent cerebrovascular events occurred within the first 48 hours, reflecting 
early ischaemic reperfusion injury, which can manifest clinically as recurrent ischaemia, 
haemorrhagic transformation of infarction, cerebral oedema and expansion of the original 
infarct. The trial was not powered to detect reductions in these events, but we observed 
tendency in favour of RIC towards reduced risk of recurrent fatal and non-fatal stroke. In 
addition, there are biochemical signals of efficacy evidenced by increased plasma 
biomarkers of brain injury (S100ß) in the placebo group not seen in the RIC group. S100ß 
is a recognised surrogate marker of infarct volume and functional outcome,19 and in this 
study correlated significantly with baseline stroke severity and day 90 mRS.  
 
It is recognised that RIC leads to an immediate period of ischaemic tolerance lasting 1-2 
hours, followed by a second window of protection (SWOP) 12-24 hours later, lasting 48-72 
hours.25 Pre-clinically, alteplase combined with RIC has an additive effect 26 and a single 
dose of RIC can have long-lasting protective effects for up to 6 days.23 Further, the time-
window of RIC application in experimental models extends up to 6 hours post-ictus 27 and 
combining per- and post-conditioning may tackle both early and late phases of ischaemic 
reperfusion injury. Per-conditioning was more effective at reducing infarct volume than a 
pre-conditioning stimulus in one study 28 but this difference is not borne out in meta-analysis 
of experimental data.7 Since strokes are difficult to predict, per-conditioning is a viable 
strategy in acute ischaemia, whereas pre-conditioning maybe more suited towards high-risk 
populations, for example, before carotid intervention,8 or after a transient ischaemic attack. 
 
A recent Cochrane Review exploring RIC for preventing and treating ischaemic stroke has 
highlighted the paucity of published randomised clinical trials in this area.29 Interestingly, 
recurrence in ischaemic stroke (by end of trial) was significantly reduced.8, 11, 12, 29 In updating 
the meta-analysis with RECAST-1,10 RECAST-2 and Che 2019,30 and organising groups 
into pre- per- and post-conditioning trials, RIC significantly reduces the composite outcome 
of recurrent vascular events, an OR 0.27 (95% CI 0.13-0.59), Figure 5.8, 10-12, 30 This is 
consistent with secondary analyses in the cardiac literature (RIC and acute myocardial 
infarction) where recurrent cardiovascular and cerebrovascular events were reduced by 
half.31 It is not intuitive that brief periods of RIC can lead to protection from vascular events 
at much later time points (and repeated doses may be required) but the finding deserves 
further exploration in clinical trials.  
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RECAST-2 was a high-quality randomised trial strengthened by assessment of multiple 
doses, concealment of allocation and blinded outcome assessments. Limitations include the 
inability to blind the investigator performing the intervention, potentially introducing bias into 
RIC/sham compliance. Second, a small sample size, which is sufficient to answer questions 
of feasibility, introduces risk that other findings may be due to chance, especially since there 
was an imbalance in systolic blood pressure and diabetes between groups at baseline; a 
larger randomised trial is needed to further evaluate efficacy and safety. Third, no 
participants undergoing mechanical thrombectomy (MT) were included (due to the need to 
deliver RIC manually and logistics of transfer to another site); we are unable to comment on 
safety of RIC in MT but RIC seems feasible and safe in an observational study of MT.32 
Finally, due to a limited budget, we did not perform any mechanistic neuroimaging studies 
that determine recanalization or reperfusion rates; however, whist use of RIC in acute 
ischaemic stroke seems most likely to benefit those with ischaemic reperfusion injury, there 
is suggestion that in patients with persisting occlusion, RIC may still reduce infarct risk.9  
 
In summary, RIC in hyperacute ischaemic stroke is feasible, appears safe and can be 
administered in repeated doses reliably for two days. It is an attractive prospect since it 
bears low cost and would be simple to administer. A larger phase III trial is warranted.  
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Table 1. Baseline characteristics 
 
 
 
 
 
 
Characteristic RIC Sham 
Number 31 29 
Age, years (SD) † 70.9 (13.4) 73.7 (10.2) 
Male (%) † 21 (70) 15 (50.0) 
Blood pressure, mmHg   
Systolic † 146 (24) 162 (23) 
Diastolic 78 (12) 83 (11) 
Heart rate 77 (13) 80 (18) 
Admission ECG in AF 11 (36.7) 12 (40.0) 
NIHSS † 6 [3-9] 7 [3-12] 
GCS 15 [14-15] 15 [14-15] 
Premorbid mRS 0 [0-2] 0 [0-1] 
Stroke to randomisation [minutes] 254 [254-343] 199 [149-261] 
Admission to randomisation [minutes] 195 [174-277] 93 [66-168] 
Thrombolysed 16 (51.6) 17 (58.6) 
Mechanical thrombectomy 0 (0) 0 (0) 
Final diagnosis (%) *   
Ischaemic stroke 28 (90.3) 27 (93.1) 
TIA 2 (6.5) 2 (6.9) 
Haemorrhagic stroke 0 (0) 0 (0) 
Clinical syndrome (%)   
Total anterior circulation 6 (20.0) 5 (16.7) 
Partial anterior circulation 9 (30.0) 14 (46.7) 
Lacunar 9 (30.0) 8 (26.7) 
Posterior circulation 4 (13.3) 0 (0.0) 
Past Medical History (%)   
Hypertension 14 (46.7) 11 (36.7) 
Diabetes mellitus 10 (33.3) 2 (6.7) 
Known AF 12 (40.0) 10 (33.3) 
Hyperlipidaemia 14 (46.7) 9 (30.0) 
Stroke 9 (30.0) 5 (16.7) 
TIA 6 (20.0) 2 (6.7) 
Ischaemic Heart Disease 5 (16.7) 4 (13.3) 
Peripheral Vascular Disease 1 (3.3) 1(3.3) 
Data presented are mean values (standard deviation), median [interquartile range]] or 
number (percentage). AF, atrial fibrillation; NIHSS, National Institute of Health Stroke 
Scale; mRS, modified Rankin scale; TIA, transient ischaemic attack; † minimisation 
variables, * one participant diagnosed with functional disorder in the RIC group. 
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Table 2  
Summary of secondary clinical outcomes and serious adverse events 
 
Serious Adverse Event 
RIC  
(n=31) 
Sham  
(n=29) HR (95% CI)  p  
No with SAE     
  Any SAE 10 (32.3) 10 (34.5) 0.81 (0.33-1.96) 0.81 
    Fatal 2 (6.5) 4 (13.8) 0.46 (0.8-2.5) 0.36 
All stroke and ND*     
Extension/recurrent ischaemic stroke 2 (6.5) 6 (20.7) 0.28 (0.06-1.37) 0.12 
Symptomatic HTI 2 (6.5) 1 (3.4) 1.85 (0.17-20.38) 0.62 
Early ND 1 (3.2) 0 (0.0) - - 
Seizure 0 (0.0) 1 (3.4) - - 
TIA 1 (3.2) 0 (0.0) - - 
MI 0 (0.0) 0 (0.0) - - 
VTE     
PE 0 (0.0) 1 (3.4) - - 
DVT 0 (0.0) 0 (0.0) - - 
SAE, serious adverse event, ND neurological deterioration, HTI haemorrhagic transformation of infarction; TIA transient 
ischaemic attack; MI, myocardial infarction; VTE, venous thrombo-embolism; PE, pulmonary embolism; DVT, deep vein 
thrombosis. Analyses performed using unadjusted Cox-regression. 
*1 participant in the sham group had ND and HTI; 1 in the RIC group had HTI and recurrent stroke (only the first event is 
counted in regression analyses). 
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Table 3 
Functional outcome by group at day 4 and day 90 
 
Functional measure RIC Sham p 
Day 4 * n=30 n=24  
NIHSS  6.4 (9.4) 9.5 (12.8) 0.30 
Change NIHSS  -3.0 (3.8) -1.4 (6.3) 0.35 
 
Day 90 n=31 n=29  
Modified Rankin Scale (/6)    
Median 2 [1, 4] 2 [1, 3] 0.85 
mRS 3-6 (%) 12 (40) 14 (46.6) 0.46 
Barthel Index (/100) 100 [65, 100] 100 [57.5, 100] 0.89 
Zung depression score ∂ 46.25 [33.75,53.75] 42.5 [37.5, 52.5] 0.94 
EuroQoL HUI ∂ 0.514 (0.377) 0.482 (0.393) 0.77 
EuroQoL VAS ∂ 70.8 (23.0) 69.8 (19.2) 0.87 
TICS-M ∂ 23 [20,25] 23.5 [21, 27] 0.89 
NIHSS, Nation Institute of Health Stroke Scale; mRS, modified Rankin scale, HUI health utility index; VAS visual analogue scale 
Data are mean (SD), median [IQR] or number (%). Imputed value for death: BI -5; NIHSS 42 
* Day 4 NIHSS - Sham n=24, RIC n=30 (data missing due to early discharge or refused) 
Analysed by independent t-test, Mann-Whitney U test or Chi square test as appropriate. 
∂ N for EuroQoL HUI: 24(sham) / 28(RIC), EuroQoL VAS 22/24, Zung 17/16, TICS-M 14/14. N reduced by: (i) carers answering on 
behalf of participants who could not respond (n=17), (ii) refused to answer questions on mood and cognition, (iii) death (n=6).  
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Figure Legends 
 
Figure 1. Trial Flow.  
 
Figure 2. Adherence to RIC (remote ischaemic conditioning) or sham by dose number and 
mean total duration of limb ischaemia (seconds ± standard deviation). Maximum length of cuff 
inflation is 300 seconds per dose (4x 5 minutes/cycle). Compared to dose 1, there is a 
significant fall in adherence over time from Day 3 (*p=0.001, **p<0.001 repeated measures 
ANOVA), with no between group differences (p=0.64). ‘n’ sham/RIC =  dose 1 29/31; dose 2 
19/21; doses 3-8 10/10. 
 
Figure 3. Plasma S100ß (A), matrix metalloproteinase-9 (MMP-9, B) and neurone specific 
enolase (NSE, C) on days 1 and 4 by treatment group. S100ß levels increase by day 4 in the 
sham group from 34.5 pg/ml (SD 37.8) to 145.6 pg/ml (309.1), mean difference 111 pg/ml (95% 
CI 5.6 - 216), p=0.041*. There were no significant between group differences at day 4. Analysis 
by repeated measures ANCOVA, Sidak’s correction for multiple comparisons and adjusted for 
baseline stroke severity. RIC = remote ischaemic conditioning. 
 
Figure 4. Day 90 modified Rankin (mRS) score by treatment group. Unadjusted common odds 
ratios (cOR) and 95% confidence intervals (CI) comparing groups are analysed by ordinal 
logistic regression. There was no significant interaction when treatment*thrombolysis was 
introduced into the model. The line demarcates dichotomy at functional independence, a 
modified Rankin score (mRS) of <2. RIC = remote ischaemic conditioning. 
 
Figure 5. Recurrent vascular events (non-fatal and fatal stroke, non-fatal and fatal myocardial 
infarction) in randomised controlled trials assessing remote ischaemic conditioning (RIC) in 
stroke. ref = reference number. 
 
  
JAHA submission, accepted version 25th Sept 2019 
 20 
Figure 1 
 
 
 
 
  
Screening †
Clinical stroke within 6 hours
Centre 1 n=1387
Centre 2 *
Randomised 1:1
RIC or sham 
(n=60)
Dose 1
RIC n=11
Sham n=9
Dose 2
RIC n=10
Sham n=10
Dose 3
RIC n=10
Sham n=10
Day 90 follow up
RIC = 9 
Sham = 8
Loss to follow up n=0
Deaths n=2 (1 RIC, 1 sham)
Loss to follow up n=0
Deaths n=3 (1 RIC, 2 sham)
Loss to follow up n=0
Deaths n=1 (1 sham)
Day 90 follow up
RIC = 10
Sham = 8
Day 90 follow up
RIC = 10
Sham = 9
†Supplementary Table I details full screening breakdown 
*Data not available from Centre 2 
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Figure 5 
 
 
JAHA submission, accepted version 25th Sept 2019 
 25 
Supplementary Table I 
Reasons for exclusion from centre 1. (Data not available from centre 2, which were discarded before analysis due to changes in 
European law on data protection (General Data Protection Regulation (GDPR), see https://eugdpr.org) 
 
Reason for exclusion N = 1387 (%) 
Greater than 6 hours since onset of symptoms 575 41.5 
Premorbid dependency mRS =/> 4 12 0.9 
Dementia 34 2.5 
Coma – GCS <8 3 0.2 
Malignancy or significant co-morbidity thought to limit life expectancy 12 0.9 
Blood glucose < 3.5mmol/L 0 0.0 
Pregnancy 0 0.0 
Out of hours 186 13.4 
Non stroke 174 12.5 
No-one to assent 8 0.6 
Trial on hold 9 0.6 
Poor prognosis/ Died 11 0.8 
Recruited 20 1.4 
Refused 7 0.5 
Out of area 1 0.1 
No English 2 0.1 
Competing trial 13 0.9 
Anaphylactic reaction to thrombolysis 2 0.1 
Resolved minor stroke 8 0.6 
TIA 119 8.6 
ICH 170 12.3 
Thrombectomy 3 0.2 
Seizures/ vomiting at presentation 1 0.1 
Researcher unavailable (e.g. annual leave, training, sick leave) 17 1.2 
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Supplementary Table II 
Reasons for non-compliance 
 
 
RIC group  
Dose 1 n=1 refused all cycles† 
Dose 2 n=1 refused all cycles†, n=4 reduced compliance (1=cuff pressure, 1=headache, 2=cannula)  
Dose 3 n=1 weekend (no researcher available to administer intervention), n=1 relative refusal, n=1 cuff pressure 
Dose 4  n=1 agitated, refused remaining doses; n=1 weekend; n=1 relative refused remaining doses; n=1 cuff pressure 
Dose 5 n=2 weekend, n=1 relative refusal, n=1 felt unwell on cuff release, remainder discharged 
Dose 6 n=2 weekend, n=1 refused (previously felt unwell with cuff release), n=1 relative refused, remainder discharged 
Dose 7 n=1 refusal, n=1 relative refusal, remainder discharged  
Dose 8 n=1 refusal, n=1 relative refusal, remainder discharged  
 
Sham 
Dose 2 n=1 deteriorated during treatment, n=1 relative refused all doses after dose 1, n=1 weekend 
Doses 3&4 n=1 weekend (no researcher available to administer intervention)  
 
† one participant refused doses 1 and 2 but was fully compliant doses 3-8        
Early discharge explains the remainder of non-compliance in the sham group   
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Supplementary Table III. Serious adverse events 
Treatment 
Group 
Trial 
number 
Thrombo
- lysis 
Time post randomisation   
(days d, hours hr, minutes 
m) Adjudicated Diagnosis 
Day 
of 
death Relationship 
Sham 11 Y 0 d, 5 hr, 58 m Extension/recurrent ischaemic stroke 3 Improbable 
 11 Y 0 d, 6 hr, 33 m Pneumonia  Improbable 
 13 N 0 d, 15 hr, 7 m Extension/recurrent ischaemic stroke  Improbable 
 13 N 0 d, 0 hr, 2 m Haematemesis  Improbable 
 13 N 3 d, 12 hr, 17 m Pulmonary embolism  Improbable 
 15 N 0 d, 9 hr, 54 m Extension/recurrent ischaemic stroke  Improbable 
 23 N 0 d, 0 hr, 36 m Extension/recurrent ischaemic stroke  Improbable 
 23 N 1 d, 21 hr, 56 m Symptomatic Haemorrhagic transformation of infarct 6 Possible 
 28 Y 0 d, 3 hr, 29 m Seizure / convulsions  Improbable 
 28 Y 0 d, 0 hr, 1 m Early neurological deterioration 4 Improbable 
  Y 0 d, 22 hr, 19 m   Asymptomatic Haemorrhagic transformation of infarct  Possible 
 41 Y 1 d, 22 hr, 20 m Pneumonia  Improbable 
 38 N 15 d, 22 hr, 39 m Traumatic rectus sheath haematoma  Improbable 
 38 N 6 d, 0 hr, 30 m Urinary tract infection  Improbable 
 41 Y 12 d, 23 hr, 11 m Pneumonia  Improbable 
 41 Y 31 d, 1 hr, 35 m Urinary tract infection  Improbable 
 41 Y 36 d, 19 hr, 35 m Complication of original stroke 47 Improbable 
 47 Y 0 d, 2 hr, 25 m Extension/recurrent ischaemic stroke  Improbable 
 53 Y 0 d, 5 hr, 46 m Extension/recurrent ischaemic stroke  Improbable 
       
RIC 9 Y 0 d, 21 hr, 7 m Extension/recurrent ischaemic stroke  Improbable 
 12 Y 0 d, 17 hr, 32 m Symptomatic Haemorrhagic transformation of infarct 2 Possible 
 16 N 2 d, 6 hr, 40 m Urinary tract infection  Improbable 
 22 Y 0 d, 0 hr, 0 m Fever, undetermined source  Improbable 
 39 N 7 d, 10 hr, 10 m Symptomatic Haemorrhagic transformation of infarct  Possible 
 39 N 1 d, 22 hr, 6 m Lung Malignancy 30 Improbable 
 39 N 21 d, 10 hr, 10 m Recurrent ischaemic stroke  Improbable 
 33 N 17 d, 17 hr, 55 m Pneumonia  Improbable 
 42 Y 2 d, 7 hr, 37 m Urinary tract infection  Improbable 
 35 Y 9 d, 20 hr, 5 m Urinary tract infection  Improbable 
 52 N 2 d, 23 hr, 23 m Transient ischaemic attack  Improbable 
 44 N 6 d, 19 hr, 55 m Pneumonia  Improbable 
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Supplementary Table IV. Serious Adverse Events and Clinical outcomes by thrombolysis 
 
Serious Adverse Event RIC  Sham  p  
Thrombolysed    
Number  16 17  
No with SAE    
  Any SAE 5 (31.3) 5 (29.4) 1.0 
    Fatal 1 (6.2) 3 (17.6) 0.60 
All stroke and ND*    
Extension/recurrent ischaemic stroke 1 (6.2) 3 (17.6) 0.60 
Symptomatic HTI 1 (6.2) 0 0.49 
Early ND 0 1 (5.9) 1.0 
Seizure 0 1 (5.9) 1.0 
Limb injury 0 0 - 
    
Not thrombolysed    
Number  15 12  
No with SAE    
    Any SAE 5 (33.3) 5 (41.7) 1.0 
    Fatal 1 (6.7) 1 (8.3) 1.0 
All stroke and ND*    
    Extension/recurrent ischaemic stroke 1 (6.7) 3 (25) 0.29 
    Symptomatic HTI 1 (6.7) 1 (8.3) 1.0 
    Early ND 0 0 - 
Seizure 0 0 - 
Limb injury 0 0 - 
Post hoc analyses, performed using 2-sided Fisher’s Exact test. Data are number (%) 
SAE, serious adverse event, ND neurological deterioration, HTI haemorrhagic transformation of 
infarction 
 
 
